Logo image of TMDX

TRANSMEDICS GROUP INC (TMDX) Stock Fundamental Analysis

NASDAQ:TMDX - Nasdaq - US89377M1099 - Common Stock - Currency: USD

71.95  -3.5 (-4.64%)

After market: 71.7 -0.25 (-0.35%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to TMDX. TMDX was compared to 190 industry peers in the Health Care Equipment & Supplies industry. TMDX has an average financial health and profitability rating. TMDX is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

TMDX had positive earnings in the past year.
In the past year TMDX had a positive cash flow from operations.
In the past 5 years TMDX always reported negative net income.
In the past 5 years TMDX always reported negative operating cash flow.
TMDX Yearly Net Income VS EBIT VS OCF VS FCFTMDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of 4.15%, TMDX is in the better half of the industry, outperforming 79.26% of the companies in the same industry.
The Return On Equity of TMDX (15.55%) is better than 90.96% of its industry peers.
Looking at the Return On Invested Capital, with a value of 3.43%, TMDX is in the better half of the industry, outperforming 73.94% of the companies in the same industry.
Industry RankSector Rank
ROA 4.15%
ROE 15.55%
ROIC 3.43%
ROA(3y)-16.47%
ROA(5y)-20.03%
ROE(3y)-34.23%
ROE(5y)-38.36%
ROIC(3y)N/A
ROIC(5y)N/A
TMDX Yearly ROA, ROE, ROICTMDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200 300 400

1.3 Margins

TMDX has a Profit Margin of 8.14%. This is in the better half of the industry: TMDX outperforms 79.79% of its industry peers.
TMDX has a better Operating Margin (7.84%) than 76.06% of its industry peers.
With a Gross Margin value of 59.34%, TMDX perfoms like the industry average, outperforming 57.45% of the companies in the same industry.
TMDX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 7.84%
PM (TTM) 8.14%
GM 59.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.58%
GM growth 5Y7.7%
TMDX Yearly Profit, Operating, Gross MarginsTMDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TMDX is destroying value.
TMDX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TMDX has been increased compared to 5 years ago.
The debt/assets ratio for TMDX is higher compared to a year ago.
TMDX Yearly Shares OutstandingTMDX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
TMDX Yearly Total Debt VS Total AssetsTMDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 3.10 indicates that TMDX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.10, TMDX is in the better half of the industry, outperforming 68.62% of the companies in the same industry.
TMDX has a Debt/Equity ratio of 2.42. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of TMDX (2.42) is worse than 85.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.42
Debt/FCF N/A
Altman-Z 3.1
ROIC/WACC0.4
WACC8.52%
TMDX Yearly LT Debt VS Equity VS FCFTMDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 8.20 indicates that TMDX has no problem at all paying its short term obligations.
The Current ratio of TMDX (8.20) is better than 89.89% of its industry peers.
A Quick Ratio of 7.33 indicates that TMDX has no problem at all paying its short term obligations.
TMDX has a Quick ratio of 7.33. This is amongst the best in the industry. TMDX outperforms 90.43% of its industry peers.
Industry RankSector Rank
Current Ratio 8.2
Quick Ratio 7.33
TMDX Yearly Current Assets VS Current LiabilitesTMDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

8

3. Growth

3.1 Past

TMDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 185.45%, which is quite impressive.
TMDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 109.09%.
The Revenue has been growing by 79.35% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)185.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%115.38%
Revenue 1Y (TTM)109.09%
Revenue growth 3Y111.22%
Revenue growth 5Y79.35%
Sales Q2Q%63.72%

3.2 Future

Based on estimates for the next years, TMDX will show a very strong growth in Earnings Per Share. The EPS will grow by 53.77% on average per year.
TMDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.46% yearly.
EPS Next Y228.63%
EPS Next 2Y98.44%
EPS Next 3Y71.33%
EPS Next 5Y53.77%
Revenue Next Year88.31%
Revenue Next 2Y51.89%
Revenue Next 3Y40.77%
Revenue Next 5Y33.46%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TMDX Yearly Revenue VS EstimatesTMDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
TMDX Yearly EPS VS EstimatesTMDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2 4 -4 -6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 76.54, TMDX can be considered very expensive at the moment.
Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than 66.49% of the companies in the same industry.
TMDX is valuated expensively when we compare the Price/Earnings ratio to 29.63, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 48.22 indicates a quite expensive valuation of TMDX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 69.68% of the companies listed in the same industry.
TMDX is valuated expensively when we compare the Price/Forward Earnings ratio to 22.68, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 76.54
Fwd PE 48.22
TMDX Price Earnings VS Forward Price EarningsTMDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

66.49% of the companies in the same industry are more expensive than TMDX, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 55.16
TMDX Per share dataTMDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TMDX's earnings are expected to grow with 71.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.33
PEG (5Y)N/A
EPS Next 2Y98.44%
EPS Next 3Y71.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TMDX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRANSMEDICS GROUP INC

NASDAQ:TMDX (2/21/2025, 8:00:01 PM)

After market: 71.7 -0.25 (-0.35%)

71.95

-3.5 (-4.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-28 2024-10-28/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners115.59%
Inst Owner Change0.67%
Ins Owners3.16%
Ins Owner Change2.59%
Market Cap2.41B
Analysts81.18
Price Target113.11 (57.21%)
Short Float %34.27%
Short Ratio5.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.77%
Min EPS beat(2)-59.86%
Max EPS beat(2)63.4%
EPS beat(4)3
Avg EPS beat(4)312.78%
Min EPS beat(4)-59.86%
Max EPS beat(4)957.84%
EPS beat(8)6
Avg EPS beat(8)131.87%
EPS beat(12)8
Avg EPS beat(12)89.63%
EPS beat(16)10
Avg EPS beat(16)63.89%
Revenue beat(2)1
Avg Revenue beat(2)2.97%
Min Revenue beat(2)-7.28%
Max Revenue beat(2)13.23%
Revenue beat(4)3
Avg Revenue beat(4)8.86%
Min Revenue beat(4)-7.28%
Max Revenue beat(4)16.17%
Revenue beat(8)7
Avg Revenue beat(8)15.29%
Revenue beat(12)11
Avg Revenue beat(12)22.22%
Revenue beat(16)13
Avg Revenue beat(16)17.29%
PT rev (1m)-0.66%
PT rev (3m)-39.4%
EPS NQ rev (1m)-15.79%
EPS NQ rev (3m)-28.71%
EPS NY rev (1m)-0.1%
EPS NY rev (3m)-9.06%
Revenue NQ rev (1m)-1.68%
Revenue NQ rev (3m)-2.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.89%
Valuation
Industry RankSector Rank
PE 76.54
Fwd PE 48.22
P/S 6.02
P/FCF N/A
P/OCF 64.49
P/B 11.5
P/tB 12.31
EV/EBITDA 55.16
EPS(TTM)0.94
EY1.31%
EPS(NY)1.49
Fwd EY2.07%
FCF(TTM)-3.59
FCFYN/A
OCF(TTM)1.12
OCFY1.55%
SpS11.95
BVpS6.26
TBVpS5.85
PEG (NY)0.33
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.15%
ROE 15.55%
ROCE 4.34%
ROIC 3.43%
ROICexc 6.28%
ROICexgc 6.51%
OM 7.84%
PM (TTM) 8.14%
GM 59.34%
FCFM N/A
ROA(3y)-16.47%
ROA(5y)-20.03%
ROE(3y)-34.23%
ROE(5y)-38.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.58%
GM growth 5Y7.7%
F-Score6
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 2.42
Debt/FCF N/A
Debt/EBITDA 10.35
Cap/Depr 893.16%
Cap/Sales 39.38%
Interest Coverage 250
Cash Conversion 76.19%
Profit Quality N/A
Current Ratio 8.2
Quick Ratio 7.33
Altman-Z 3.1
F-Score6
WACC8.52%
ROIC/WACC0.4
Cap/Depr(3y)797.55%
Cap/Depr(5y)487.14%
Cap/Sales(3y)29.07%
Cap/Sales(5y)17.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)185.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%115.38%
EPS Next Y228.63%
EPS Next 2Y98.44%
EPS Next 3Y71.33%
EPS Next 5Y53.77%
Revenue 1Y (TTM)109.09%
Revenue growth 3Y111.22%
Revenue growth 5Y79.35%
Sales Q2Q%63.72%
Revenue Next Year88.31%
Revenue Next 2Y51.89%
Revenue Next 3Y40.77%
Revenue Next 5Y33.46%
EBIT growth 1Y187.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year274.38%
EBIT Next 3Y84.16%
EBIT Next 5Y65.17%
FCF growth 1Y-98.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y177.33%
OCF growth 3YN/A
OCF growth 5YN/A